DZNep inhibits Hif‑1α and Wnt signalling molecules to attenuate the proliferation and invasion of BGC‑823 gastric cancer cells

Huang,Rui; Jin,Xiu; Gao,Yongying; Yuan,Hongmei; Wang,Fei; Cao,Xiangmei

doi:10.3892/ol.2019.10769

DZNep inhibits Hif‑1α and Wnt signalling molecules to attenuate the proliferation and invasion of BGC‑823 gastric cancer cells

Authors:
- Rui Huang
- Xiu Jin
- Yongying Gao
- Hongmei Yuan
- Fei Wang
- Xiangmei Cao
View Affiliations

Affiliations: Department of Gastroenterology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China, Department of Pathology, Basic Medical School, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China, Department of Neurology, Ningxia People's Hospital, Yinchuan, Ningxia 750021, P.R. China, Department of Ultrasound, Ningxia People's Hospital, Yinchuan, Ningxia 750021, P.R. China
Published online on: August 22, 2019 https://doi.org/10.3892/ol.2019.10769
Pages: 4308-4316

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

3‑deazaneplanocin A (DZNep) is a histone methyltransferase inhibitor, which may cause the reactivation of silenced tumor suppressor genes in tumors to inhibit the development, metastasis and dissemination of tumor cells. However, the effects and mechanisms of its application in gastric cancer remain unclear. The present study revealed an inhibitory function of DZNep in BGC‑823 cells. The cell colony, Cell Counting Kit‑8 (CCK8), wound healing, Transwell and flow cytometry assays were performed, and the results demonstrated that DZNep could inhibit the proliferation, apoptosis and invasion of BGC‑823 cells, and promote their apoptosis. The effects of intervention in BDC‑823 cells with DZNep on the RNA and protein expression levels of hypoxia‑inducible factor (Hif‑1α) and Wnt/β‑catenin signalling molecules were further examined using reverse transcription‑quantitative PCR and western blot analysis. The results demonstrated that different concentrations of DZNep could inhibit the expression of enhancer of zeste homolog 2 (EZH2) protein, decrease the RNA and protein expression levels of Hif‑1α, total β‑catenin and phosphorylated‑β‑catenin and increase the expression levels of non‑phosphorylated‑β‑catenin to different degrees. The results of the present study suggests that DZNep inhibits BGC‑823 gastric cancer cells via the inhibition of EZH2, Hif‑1α and Wnt/β‑catenin signalling molecules. These results provide theoretical basis for the application of DZNep in clinical trials.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D and Osteen R: Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 218:583–592. 1993. View Article : Google Scholar : PubMed/NCBI
3	Koeda K, Nishizuka S and Wakabayashi G: Minimally invasive surgery for gastric cancer: The future standard of care. World J Surg. 35:1469–1477. 2011. View Article : Google Scholar : PubMed/NCBI
4	Piunti A and Pasini D: Epigenetic factors in cancer development: Polycomb group proteins. Future Oncol. 7:57–75. 2011. View Article : Google Scholar : PubMed/NCBI
5	Gergely JE, Dorsey AE, Dimri GP and Dimri M: Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells. Mol Carcinog. 57:831–841. 2018. View Article : Google Scholar : PubMed/NCBI
6	Margueron R and Reinberg D: The polycomb complex PRC2 and its mark in life. Nature. 469:343–349. 2011. View Article : Google Scholar : PubMed/NCBI
7	Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, et al: EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69:9211–9218. 2009. View Article : Google Scholar : PubMed/NCBI
8	Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD and Wistuba II: Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. Cancer Res. 76:675–685. 2016. View Article : Google Scholar : PubMed/NCBI
9	Jung HY, Jun S, Lee M, Kim HC, Wang X, Ji H, McCrea PD and Park JI: PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation. Mol Cell. 52:193–205. 2013. View Article : Google Scholar : PubMed/NCBI
10	Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE and Jones PA: DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 8:1579–1588. 2009. View Article : Google Scholar : PubMed/NCBI
11	Mochizuki D, Misawa Y, Kawasaki H, Imai A, Endo S, Mima M, Yamada S, Nakagawa T, Kanazawa T and Misawa K: Aberrant epigenetic regulation in head and neck cancer due to distinct EZH2 overexpression and dna hypermethylation. Int J Mol Sci. 19(pii): E37072018. View Article : Google Scholar : PubMed/NCBI
12	Yao Y, Hu H, Yang Y, Zhou G, Shang Z, Yang X, Sun K, Zhan S, Yu Z, Li P, et al: Downregulation of enhancer of zeste homolog 2 (EZH2) is essential for the induction of autophagy and apoptosis in colorectal cancer cells. Genes (Basel). 7:832016. View Article : Google Scholar
13	Wei FZ, Cao Z, Wang X, Wang H, Cai MY, Li T, Hattori N, Wang D, Du Y, Song B, et al: Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy. 11:2309–2322. 2015. View Article : Google Scholar : PubMed/NCBI
14	Hebert M, Potin S, Sebbagh M, Bertoglio J, Bréard J and Hamelin J: Rho-ROCK-dependent ezrin-radixin-moesin phosphorylation regulates Fas-mediated apoptosis in Jurkat cells. J Immunol. 181:5963–5973. 2008. View Article : Google Scholar : PubMed/NCBI
15	Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG and Semenza GL: Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 105:659–669. 2005. View Article : Google Scholar : PubMed/NCBI
16	Qi C, Zhang J, Chen X, Wan J, Wang J, Zhang P and Liu Y: Hypoxia stimulates neural stem cell proliferation by increasing HIF-1α expression and activating Wnt/β-catenin signaling. Cell Mol Biol (Noisy-le-grand). 63:12–19. 2017. View Article : Google Scholar : PubMed/NCBI
17	Pang B, Zheng XR, Tian JX, Gao TH, Gu GY, Zhang R, Fu YB, Pang Q, Li XG and Liu Q: EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression of EAF2-HIF1α signaling. Oncotarget. 7:45134–45143. 2016. View Article : Google Scholar : PubMed/NCBI
18	Chen Q, Cai J, Wang Q, Wang Y, Liu M, Yang J, Zhou J, Kang C, Li M and Jiang C: Long noncoding RNA NEAT1, regulated by the EGFR pathway, contributes to glioblastoma progression through the WNT/β-catenin pathway by scaffolding EZH2. Clin Cancer Res. 24:684–695. 2018. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Panousis D, Patsouris E, Lagoudianakis E, Pappas A, Kyriakidou V, Voulgaris Z, Xepapadakis G, Manouras A, Athanassiadou AM and Athanassiadou P: The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors. Eur J Gynaecol Oncol. 32:156–159. 2011.PubMed/NCBI
21	Choi JH, Song YS, Yoon JS, Song KW and Lee YY: Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. Apmis. 118:196–202. 2010. View Article : Google Scholar : PubMed/NCBI
22	Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, et al: TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res. 18:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI
23	Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN and Hung MC: EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-catenin signaling. Cancer Cell. 19:86–100. 2011. View Article : Google Scholar : PubMed/NCBI
24	Glazer RI, Hartman KD, Knode MC, Richard MM, Chiang PK, Tseng CK and Marquez VE: 3-Deazaneplanocin: A new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun. 135:688–694. 1986. View Article : Google Scholar : PubMed/NCBI
25	Liu S, Liu F, Huang W, Gu L, Meng L, Ju Y, Wu Y, Li J, Liu L and Sang M: MAGE-A11 is activated through TFCP2/ZEB1 binding sites de-methylation as well as histone modification and facilitates ESCC tumor growth. Oncotarget. 9:3365–3378. 2017.PubMed/NCBI
26	Sha M, Mao G, Wang G, Chen Y, Wu X and Wang Z: DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis. Acta Pharm Sin B. 5:188–193. 2015. View Article : Google Scholar : PubMed/NCBI
27	Huang Y, Lin D and Taniguchi CM: Hypoxia inducible factor (HIF) in the tumor microenvironment: Friend or foe? Sci China Life Sci. 60:1114–1124. 2017. View Article : Google Scholar : PubMed/NCBI
28	Martin JD, Fukumura D, Duda DG, Boucher Y and Jain RK: Reengineering the tumor microenvironment to alleviate hypoxia and overcome cancer heterogeneity. Cold Spring Harb Perspect Med. 6(pii): a0270942016. View Article : Google Scholar : PubMed/NCBI
29	Li DW, Dong P, Wang F, Chen XW, Xu CZ and Zhou L: Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1α. Asian Pac J Cancer Prev. 14:4853–4858. 2013. View Article : Google Scholar : PubMed/NCBI
30	Borsi E, Terragna C, Brioli A, Tacchetti P, Martello M and Cavo M: Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. Transl Res. 165:641–650. 2015. View Article : Google Scholar : PubMed/NCBI
31	Lou JJ, Chua YL, Chew EH, Gao J, Bushell M and Hagen T: Inhibition of hypoxia-inducible factor-1alpha protein synthesis by DNA damage inducing agents. PLoS One. 5:e105222010. View Article : Google Scholar : PubMed/NCBI
32	Michel G, Minet E, Ernest I, Durant F, Remacle J and Michiels C: Molecular modeling of the hypoxia-inducible factor-1 (HIF-1). Theor Chem Acc. 101:51–56. 1999. View Article : Google Scholar
33	Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN and Hung MC: EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell. 19:86–100. 2011. View Article : Google Scholar : PubMed/NCBI
34	Mahara S, Lee PL, Feng M, Tergaonkar V, Chng WJ and Yu Q: HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proc Natl Acad Sci USA. 113:E3735–E3744. 2016. View Article : Google Scholar : PubMed/NCBI
35	Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21:1050–1063. 2007. View Article : Google Scholar : PubMed/NCBI
36	Tsang DP and Cheng AS: Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2. J Gastroenterol Hepatol. 26:19–27. 2011. View Article : Google Scholar : PubMed/NCBI
37	Zhang J, Chen L, Han L, Shi Z, Zhang J, Pu P and Kang C: EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. Cancer Lett. 356:929–936. 2015. View Article : Google Scholar : PubMed/NCBI
38	Lu H, Sun J, Wang F, Feng L, Ma Y, Shen Q, Jiang Z, Sun X, Wang X and Jin H: Enhancer of zeste homolog 2 activates Wnt signaling through downregulating CXXC finger protein 4. Cell Death Dis. 4:e7762013. View Article : Google Scholar : PubMed/NCBI
39	Minde DP, Radli M, Forneris F, Maurice MM and Rüdiger SG: Large extent of disorder in Adenomatous Polyposis Coli offers a strategy to guard Wnt signalling against point mutations. PLoS One. 8:e772572013. View Article : Google Scholar : PubMed/NCBI